Neos, Shire settle patent litigation related to oral ER amphetamine polistirex
Executive Summary
Neos Therapeutics Inc. (oral drug delivery technologies) settled patent litigation with Shire PLC surrounding Neos’ NT0202 (amphetamine polistirex), which, upon FDA approval, would be the first available extended-release orally disintegrating tablet form of amphetamine for attention deficit hyperactivity disorder. Shire’s lawsuit filed in April 2013 alleged that Neos infringed on two US patents when it filed for its NDA. Under the settlement, Shire grants Neos rights to use the patents to make, market, and sell NT0202, and in return Shire receives sales royalties until patent expiration.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice